Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 7/20 | 0.34 |
| ▸ | CA2 | P00918 | 7/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 7/20 | 0.33 |
| ▸ | CA9 | Q16790 | 5/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17301885 | 1.00 | APLNR (0.36) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL25143061 | 1.00 | APLNR (0.36) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL17337904 | 1.00 | APLNR (0.36) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL16133570 | 1.00 | APLNR (0.36) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL17926776 | 1.00 | APLNR (0.36) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL5494091 | 0.93 | APLNR (0.40) | APLNRTDP1CA1CA2CA7 | |
| SCHEMBL18906375 | 0.91 | BLM (0.35) | APLNRTDP1CA1CA7MAOA | |
| SCHEMBL18907006 | 0.91 | BLM (0.35) | APLNRTDP1CA1CA7MAOA | |
| SCHEMBL12142875 | 0.89 | TDP1 (0.39) | APLNRTDP1CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL20450582 | 0.87 | TDP1 (0.38) | APLNRTDP1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133340-A1 | ANTIBODY-DRUG CONJUGATES | CHO Pharma Inc. (TW) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133340-A1 | ANTIBODY-DRUG CONJUGATES | CSGALNACT1, ST6GAL1, PA2G4 | APLNR 3571/4885TDP1 2918/4885CA1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.